COCP
Cocrystal Pharma Inc
NASDAQ · Pharmaceuticals
$0.97
+0.11 (+12.75%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.74M | 2.80M | 3.00M |
| Net Income | 504.5K | 668.5K | 544.9K |
| EPS | — | — | — |
| Profit Margin | 18.4% | 23.9% | 18.1% |
| Rev Growth | +19.3% | -9.2% | +14.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 4.57M | 4.61M | 4.63M |
| Total Equity | 4.98M | 4.99M | 5.80M |
| D/E Ratio | 0.92 | 0.92 | 0.80 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 921.2K | 997.7K | 969.2K |
| Free Cash Flow | 728.8K | 746.2K | 561.0K |